ReviewCell transplantation
The anti-inflammatory effects of mesenchymal stem cells and their research progress in hematopoietic stem cell transplantation: A comprehensive review.
Review in Cell transplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hematopoietic stem cell transplantation (HSCT) is frequently accompanied by severe inflammation-related complications, among which graft-versus-host disease (GVHD) stands out as one of the most common and life-threatening. As a systemic inflammatory disorder, GVHD arises when donor T cells recognize the recipient's alloantigens and initiate an immune attack. Currently, effective second-line treatment options remain scarce for patients with antibiotic-resistant or steroid-refractory GVHD. Mesenchymal stem cells (MSCs) are non-hematopoietic cells widely distributed in fetal and adult tissues and organs, endowed with multipotent differentiation potential and prominent immunomodulatory properties. Emerging evidence suggests that impaired function or apoptosis of MSCs exacerbates HSCT-associated complications and significantly compromises hematopoietic stem cell engraftment. Over the past two decades, leveraging their potent anti-inflammatory and immunomodulatory capacities, MSCs have been rapidly integrated into HSCT research and clinical practice, where they play a pivotal role in promoting hematopoietic engraftment and preventing or treating GVHD. This review elaborates on the molecular basis of MSCs' anti-inflammatory effects and the inflammatory pathological characteristics of HSCT-related complications. We conducted a systematic literature search in PubMed, Web of Science, and Embase databases up to December 2025. The search strategy combined the following terms: ("mesenchymal stem cells" OR "MSCs") AND ("hematopoietic stem cell transplantation" OR "HSCT") AND ("graft-versus-host disease" OR "GVHD") AND ("inflammation" OR "immune regulation"). It systematically analyzes the molecular mechanisms underlying MSCs' anti-inflammatory actions and their application progress in HSCT, aiming to provide a theoretical foundation and translational insights for the rational clinical application of MSCs in HSCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.